Refine by:
-
Letter to Congressional Leadership on Medicaid and Criminal Justice
Letter urging House and Senate leadership to pass the Reentry Act (H.R.2400/S.1165) and Due Process Continuity of Care Act (H.R.3074/S.971) before the end of the 118th Congress. -
Letter to Congressional Leadership on Due Process Continuity of Care Act and the Re-entry Act
Letter from over 66 organizations representing behavioral health and criminal justice, to Senate and House leadership requesting that they pass the Reentry Act (H.R. 2400/S. 1165) and Due Process Continuity of Care Act (H.R. 3074/S. 971) by the end of the session. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter urging Congress to finalize the Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) spending bill by the end of the calendar year with a robust investment in the NIH. -
Letter to Congressional Committee Leadership on Child and Adolescent Mental Health
Letter urging the Senate HELP and House Energy and Commerce Committees to include the bipartisan Kid Providing Resources for Optimal Outcomes Against Fatalities Act (Kid PROOF) in the reauthorization of the SUPPORT Act. -
Letter to Congressional Leadership on Research and Innovation
Letter to House and Senate committee leaders expressing strong support for the COMPLETE Care Act (HR 5819/S. 1378) legislation, which would help clinicians adopt integrated behavioral health care delivery models. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter requesting that Congress include the $5 million for the FDA’s Neurology Drug Program, as proposed by the Senate Appropriations Committee. -
Regulatory Comment to HHS on Health Coverage
Regulatory comment to Secretary Becerra and Administrator Brooks-LaSure in support of the Notice of Benefit and Payment Parameters for 2026 Proposed Rule, and offering comments to strengthen the rule. -
Letter to Congressional Leadership on Mental Health Funding
Letter to House and Senate Leadership urging the passage of full funding for the FY25 Appropriations Package and the reauthorization of the SUPPORT Act, in an end-of-year omnibus. -
Regulatory Comment on Medication Access
Regulatory comment encouraging FDA to remove barriers to care by allowing patients the choice to opt out of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) after the initial highest risk period and to allow for emergency prescriptions when the administrative barriers are not met. -
Letter to Congressional Leadership on Maternal Mental Health
Letter to Congressional leadership urging the inclusion of the bipartisan Preventing Maternal Deaths Reauthorization Act in the final FY 2025 appropriations package or any other must-pass legislative package.